Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

So we now know we have a nasal administered anti-viral going through dose strategy testing in-vivo.

Viruses generally enter into the upper airways and nose just by breathing or touching ones face and in doing so viral replication begins. My take is since B kills viruses by contact seems a perfect early treatment route.

If B keeps proving out as a broad spectrum anti-viral it may also work well as a onset treatment against nasty cold viruses.